PKCε

PKCε is a novel protein kinase C isoform that functions as a serine/threonine signaling kinase and regulates proliferation, survival, motility, apoptosis, chemoresistance, and differentiation[1]. Mechanistically, PKCε connects receptor-driven DAG/phorbol ester-responsive signaling to oncogenic nodes including RhoA/C, STAT3, Akt, Rac1, EGFR-PLCγ, and p70S6K-linked insulin signaling[1][2][3]. In ischemia models, PKCε selectively translocates during ischemic preconditioning, and PKCε gene disruption abolishes infarct-size reduction in isolated mouse hearts[4][5]. In NSCLC models, PKCε supports Rac activation, membrane ruffling, migration, invasion, metastatic dissemination, and tumor growth[2][6]. Compared with related isoforms, PKCε shows a distinct profile: novel PKCs do not require calcium, PKCα and PKCδ can induce arrest in NSCLC cells, and PKCε instead drives G1-to-S progression and survival[1][2]. For experimental applications, εV1-2 pharmacologically inhibits PKCε-dependent Rac activation and motility, while εPKC activator peptides mimic ischemic preconditioning and contrast with δPKC inhibition in reperfusion injury studies[2][7].
References:

All Product Categories

  • PKCε 관련 제품 (29)

  • Antibodies (1)

Assay Types